HRP20240871T1 - Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata - Google Patents
Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata Download PDFInfo
- Publication number
- HRP20240871T1 HRP20240871T1 HRP20240871TT HRP20240871T HRP20240871T1 HR P20240871 T1 HRP20240871 T1 HR P20240871T1 HR P20240871T T HRP20240871T T HR P20240871TT HR P20240871 T HRP20240871 T HR P20240871T HR P20240871 T1 HRP20240871 T1 HR P20240871T1
- Authority
- HR
- Croatia
- Prior art keywords
- subject
- use according
- rhtpp1
- preparation
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893535P | 2019-08-29 | 2019-08-29 | |
| EP20771408.0A EP4021575B1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
| PCT/US2020/048704 WO2021042020A1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240871T1 true HRP20240871T1 (hr) | 2024-10-11 |
Family
ID=72470612
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240871TT HRP20240871T1 (hr) | 2019-08-29 | 2020-08-31 | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata |
| HRP20220370AA HRP20220370A1 (hr) | 2019-08-29 | 2020-08-31 | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220370AA HRP20220370A1 (hr) | 2019-08-29 | 2020-08-31 | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata |
Country Status (24)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303693B2 (en) * | 2021-04-02 | 2025-05-20 | Neuropace, Inc. | Systems and methods for controlling operation of an implanted neurostimulation system based on a mapping of episode durations and seizure probability biomarkers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| CA2803166C (en) * | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| AU2016341428B2 (en) * | 2015-10-23 | 2021-12-02 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| KR20260086827A (ko) * | 2018-11-14 | 2026-06-10 | 리젠엑스바이오 인크. | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 |
-
2020
- 2020-08-31 EP EP24177169.0A patent/EP4438120A3/en active Pending
- 2020-08-31 LT LTEPPCT/US2020/048704T patent/LT4021575T/lt unknown
- 2020-08-31 CN CN202080068971.3A patent/CN114828960A/zh active Pending
- 2020-08-31 KR KR1020227010387A patent/KR20220054375A/ko active Pending
- 2020-08-31 EP EP20771408.0A patent/EP4021575B1/en active Active
- 2020-08-31 US US17/638,029 patent/US20220273775A1/en active Pending
- 2020-08-31 HR HRP20240871TT patent/HRP20240871T1/hr unknown
- 2020-08-31 WO PCT/US2020/048704 patent/WO2021042020A1/en not_active Ceased
- 2020-08-31 FI FIEP20771408.0T patent/FI4021575T3/fi active
- 2020-08-31 MX MX2022002451A patent/MX2022002451A/es unknown
- 2020-08-31 CA CA3152521A patent/CA3152521A1/en active Pending
- 2020-08-31 HU HUE20771408A patent/HUE067135T2/hu unknown
- 2020-08-31 AU AU2020336984A patent/AU2020336984B2/en active Active
- 2020-08-31 AR ARP200102442A patent/AR119871A1/es unknown
- 2020-08-31 JP JP2022513165A patent/JP2022546042A/ja active Pending
- 2020-08-31 ES ES20771408T patent/ES2987156T3/es active Active
- 2020-08-31 RS RS20240792A patent/RS65763B1/sr unknown
- 2020-08-31 PL PL20771408.0T patent/PL4021575T3/pl unknown
- 2020-08-31 SM SM20240315T patent/SMT202400315T1/it unknown
- 2020-08-31 SI SI202030455T patent/SI4021575T1/sl unknown
- 2020-08-31 PT PT207714080T patent/PT4021575T/pt unknown
- 2020-08-31 DK DK20771408.0T patent/DK4021575T3/da active
- 2020-08-31 BR BR112022003598A patent/BR112022003598A2/pt unknown
- 2020-08-31 HR HRP20220370AA patent/HRP20220370A1/hr not_active Application Discontinuation
-
2022
- 2022-02-21 IL IL290763A patent/IL290763A/en unknown
- 2022-02-28 CL CL2022000496A patent/CL2022000496A1/es unknown
-
2025
- 2025-08-12 JP JP2025134120A patent/JP2025165414A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202611A patent/AU2026202611A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021575B1 (en) | 2024-05-22 |
| JP2022546042A (ja) | 2022-11-02 |
| PL4021575T3 (pl) | 2024-09-23 |
| ES2987156T3 (es) | 2024-11-14 |
| HUE067135T2 (hu) | 2024-10-28 |
| MX2022002451A (es) | 2022-06-02 |
| RS65763B1 (sr) | 2024-08-30 |
| KR20220054375A (ko) | 2022-05-02 |
| SMT202400315T1 (it) | 2024-09-16 |
| FI4021575T3 (fi) | 2024-07-24 |
| EP4021575A1 (en) | 2022-07-06 |
| PT4021575T (pt) | 2024-07-30 |
| LT4021575T (lt) | 2024-08-12 |
| AR119871A1 (es) | 2022-01-19 |
| AU2020336984B2 (en) | 2026-04-23 |
| TW202122106A (zh) | 2021-06-16 |
| US20220273775A1 (en) | 2022-09-01 |
| WO2021042020A1 (en) | 2021-03-04 |
| HRP20220370A1 (hr) | 2022-09-16 |
| CL2022000496A1 (es) | 2022-10-21 |
| JP2025165414A (ja) | 2025-11-04 |
| SI4021575T1 (sl) | 2024-10-30 |
| CN114828960A (zh) | 2022-07-29 |
| EP4438120A2 (en) | 2024-10-02 |
| AU2020336984A1 (en) | 2022-03-10 |
| IL290763A (en) | 2022-04-01 |
| AU2026202611A1 (en) | 2026-06-04 |
| CA3152521A1 (en) | 2021-03-04 |
| EP4438120A3 (en) | 2024-12-11 |
| BR112022003598A2 (pt) | 2022-05-24 |
| DK4021575T3 (da) | 2024-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2007528352A (ja) | 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療 | |
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
| WO2016040169A2 (en) | Methods of treating pulmonary sarcoidosis | |
| HARRELL et al. | The treatment of North American blastomycosis with amphotericin B | |
| Shao et al. | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone | |
| JP4276779B2 (ja) | 注意欠損/活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| FI4021575T3 (fi) | Menetelmiä cln2-taudin hoitamiseksi lapsikohteissa | |
| Fiore et al. | Neuroleptic malignant-like syndrome (NMLS) in a patient with parkinson's disease resolved with rotigotine | |
| JP2022546042A5 (cg-RX-API-DMAC7.html) | ||
| Mychka et al. | Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome | |
| CN104138389B (zh) | 治疗血液循环障碍类疾病的药物组合物 | |
| RU2468813C1 (ru) | Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения | |
| BAKHSHAYESH et al. | Comparing the effect of memantine and placebo on clinical outcome of intracranial hemorrhage: a randomized double blind clinical trial | |
| Wu et al. | Antifreeze poisoning: A case report | |
| CN104056080A (zh) | 一种治疗脑血栓后遗症的中药组合物 | |
| CN102727710B (zh) | 一种治疗再生障碍性贫血药物 | |
| NAIDE | DIPHENHYDRAMINE (BENADRYL®) FOR NOCTURNAL LEG CRAMPS | |
| Westelinck et al. | Low dose guanfacine once-a-day for the treatment of hypertension in general practice: a multi-centre pilot study | |
| WANG et al. | Clinical Efficacy of Jiuzi Huichun Decoction Combined with Spleen-strengthening Moxibustion on Asthenospermia Infertility with Spleen-kidney Deficiency Pattern | |
| EA202192740A1 (ru) | Фармацевтический набор и способ лечения воспалительных процессов | |
| Karki et al. | Thyrotoxicosis Induced Hypokalemic Periodic Paralysis in Organophosphorous Poisoning: A Case Report | |
| Beckerly et al. | Pharmacologic Management of Complex Regional Pain Syndrome | |
| CASSEL et al. | Acute pancreatitis in pregnancy |